Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 111 articles:
HTML format



Single Articles


    January 2021
  1. QUAGLIA F, Krishn SR, Wang Y, Goodrich DW, et al
    Differential expression of alphaVbeta3 and alphaVbeta6 integrins in prostate cancer progression.
    PLoS One. 2021;16:e0244985.
    PubMed     Abstract available


  2. LABRECQUE MP, Brown LG, Coleman IM, Nguyen HM, et al
    Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
    PLoS One. 2021;16:e0245602.
    PubMed     Abstract available


  3. OLDE HEUVEL J, de Wit-van der Veen BJ, Sinaasappel M, Slump CH, et al
    Early differences in dynamic uptake of 68Ga-PSMA-11 in primary prostate cancer: A test-retest study.
    PLoS One. 2021;16:e0246394.
    PubMed     Abstract available


  4. GUEST C, Harris R, Sfanos KS, Shrestha E, et al
    Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer.
    PLoS One. 2021;16:e0245530.
    PubMed     Abstract available


  5. WANG Y, Wang J, Tang Q, Ren G, et al
    Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.
    PLoS One. 2021;16:e0247827.
    PubMed     Abstract available


  6. KARLSSON AA, Hao S, Jauhiainen A, Elfstrom KM, et al
    The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
    PLoS One. 2021;16:e0246674.
    PubMed     Abstract available


  7. GRAYSON KA, Jyotsana N, Ortiz-Otero N, King MR, et al
    Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
    PLoS One. 2021;16:e0246733.
    PubMed     Abstract available


  8. JEONG JU, Nam TK, Song JY, Yoon MS, et al
    Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
    PLoS One. 2021;16:e0248461.
    PubMed     Abstract available


  9. LIMA CA, da Silva BEB, Hora EC, Lima MS, et al
    Trends in prostate cancer incidence and mortality to monitor control policies in a northeastern Brazilian state.
    PLoS One. 2021;16:e0249009.
    PubMed     Abstract available


  10. ZIAYEE F, Ullrich T, Blondin D, Irmer H, et al
    Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    PLoS One. 2021;16:e0249532.
    PubMed     Abstract available


  11. KHAIRNAR R, Pugh SL, Sandler HM, Lee WR, et al
    Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
    PLoS One. 2021;16:e0249123.
    PubMed     Abstract available


  12. CHUNG JW, Kim HT, Ha YS, Lee EH, et al
    Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
    PLoS One. 2021;16:e0250254.
    PubMed     Abstract available


  13. ZHANG P, Tan X, Zhang D, Gong Q, et al
    Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis.
    PLoS One. 2021;16:e0249951.
    PubMed     Abstract available


  14. YADAV MP, Ballal S, Sahoo RK, Tripathi M, et al
    Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
    PLoS One. 2021;16:e0251375.
    PubMed     Abstract available


  15. SAIDOVA AA, Potashnikova DM, Tvorogova AV, Paklina OV, et al
    Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer.
    PLoS One. 2021;16:e0251961.
    PubMed     Abstract available



  16. Retraction: Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer.
    PLoS One. 2021;16:e0253350.
    PubMed    


  17. LOUGHNEY L, McGowan R, O'Malley K, McCaffrey N, et al
    Perceptions of wellbeing and quality of life following participation in a community-based pre-operative exercise programme in men with newly diagnosed prostate cancer: A qualitative pilot study.
    PLoS One. 2021;16:e0253018.
    PubMed     Abstract available


  18. PAROL-KULCZYK M, Gzil A, Maciejewska J, Bodnar M, et al
    Clinicopathological significance of the EMT-related proteins and their interrelationships in prostate cancer. An immunohistochemical study.
    PLoS One. 2021;16:e0253112.
    PubMed     Abstract available


  19. KIM SI, Szeto AH, Morgan KP, Brower B, et al
    A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    PLoS One. 2021;16:e0253021.
    PubMed     Abstract available


  20. GUERRIERO I, Ramberg H, Sagini K, Ramirez-Garrastacho M, et al
    Implication of beta2-adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells.
    PLoS One. 2021;16:e0253828.
    PubMed     Abstract available


  21. JIANG X, Renkema H, Smeitink J, Beyrath J, et al
    Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth.
    PLoS One. 2021;16:e0254315.
    PubMed     Abstract available


  22. SALMI F, Maachi F, Tazzite A, Aboutaib R, et al
    Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.
    PLoS One. 2021;16:e0254101.
    PubMed     Abstract available


  23. RUNDLE AG, Sadasivan SM, Chitale DA, Gupta NS, et al
    Racial differences in the systemic inflammatory response to prostate cancer.
    PLoS One. 2021;16:e0252951.
    PubMed     Abstract available


  24. ZHANG H, Doucette C, Yang H, Bandyopadhyay S, et al
    Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy.
    PLoS One. 2021;16:e0253936.
    PubMed     Abstract available


  25. BARRY DELONGCHAMPS N, Schull A, Anract J, Abecassis JP, et al
    Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
    PLoS One. 2021;16:e0252040.
    PubMed     Abstract available


  26. ARIK A, Dodd E, Cairns A, Streftaris G, et al
    Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality.
    PLoS One. 2021;16:e0253854.
    PubMed     Abstract available


  27. FALLARA G, Gedeborg R, Bill-Axelson A, Garmo H, et al
    A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
    PLoS One. 2021;16:e0255239.
    PubMed     Abstract available


  28. CHO D, Milbury K, Liao Y, Pettaway CA, et al
    Study protocol: One plus one can be greater than two-Ecological momentary assessment for Black prostate cancer survivors and partners.
    PLoS One. 2021;16:e0255614.
    PubMed     Abstract available


  29. WEINER F, Schille JT, Hein JI, Wu XF, et al
    Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
    PLoS One. 2021;16:e0256468.
    PubMed     Abstract available


  30. PARK J, Park J, Oh S, Yea JW, et al
    Multi-criteria optimization for planning volumetric-modulated arc therapy for prostate cancer.
    PLoS One. 2021;16:e0257216.
    PubMed     Abstract available


  31. KIM D, Kim DY, Kim JS, Hong SK, et al
    Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy.
    PLoS One. 2021;16:e0256778.
    PubMed     Abstract available


  32. CIMORELLI M, Nieuwland R, Varga Z, van der Pol E, et al
    Standardized procedure to measure the size distribution of extracellular vesicles together with other particles in biofluids with microfluidic resistive pulse sensing.
    PLoS One. 2021;16:e0249603.
    PubMed     Abstract available


  33. TSUZUKI S, Nakanishi S, Tamaki M, Oshiro T, et al
    Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
    PLoS One. 2021;16:e0258160.
    PubMed     Abstract available


  34. MINAMITANI M, Mukai T, Yamashita H, Katano A, et al
    Effects on annual income changes after radical radiotherapy versus after prostatectomy in patients with localized prostate cancer with a specific employment status: A web-based pilot study.
    PLoS One. 2021;16:e0258116.
    PubMed     Abstract available


  35. HASHIMOTO Y, Shiina M, Maekawa S, Kato T, et al
    Suppressor effect of catechol-O-methyltransferase gene in prostate cancer.
    PLoS One. 2021;16:e0253877.
    PubMed     Abstract available


  36. VETRICHELVAN O, Gorjala P, Goodman O Jr, Mitra R, et al
    Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling and promoting G0/G1 cell cycle block and apoptosis.
    PLoS One. 2021;16:e0257984.
    PubMed     Abstract available


  37. KOGA F, Ito M, Kataoka M, Fukushima H, et al
    Novel anatomical apical dissection utilizing puboprostatic "open-collar" technique: Impact on apical surgical margin and early continence recovery.
    PLoS One. 2021;16:e0249991.
    PubMed     Abstract available


  38. GEDEBORG R, Styrke J, Loeb S, Garmo H, et al
    Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
    PLoS One. 2021;16:e0255966.
    PubMed     Abstract available


  39. CHUNG JH, Jeong JY, Lee JY, Song W, et al
    Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.
    PLoS One. 2021;16:e0249709.
    PubMed     Abstract available


    January 2020
  40. JAVAID S, Saad SM, Zafar H, Malik R, et al
    Thymidine phosphorylase and prostrate cancer cell proliferation inhibitory activities of synthetic 4-hydroxybenzohydrazides: In vitro, kinetic, and in silico studies.
    PLoS One. 2020;15:e0227549.
    PubMed     Abstract available


  41. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    PubMed     Abstract available


  42. ULYTE A, Wei W, Dressel H, Gruebner O, et al
    Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines.
    PLoS One. 2020;15:e0231409.
    PubMed     Abstract available


  43. DALY C, Logan B, Breeyear J, Whitaker K, et al
    Tks5 SH3 domains exhibit differential effects on invadopodia development.
    PLoS One. 2020;15:e0227855.
    PubMed     Abstract available


  44. HEO JE, Lee JS, Goh HJ, Jang WS, et al
    Urethral realignment with maximal urethral length and bladder neck preservation in robot-assisted radical prostatectomy: Urinary continence recovery.
    PLoS One. 2020;15:e0227744.
    PubMed     Abstract available


  45. MEDHIN LB, Achila OO, Syum BE, Gebremichael KH, et al
    Incidence of prostate cancer in Eritrea: Data from the National Health Laboratory, Orotta Referral Hospital and Sembel Hospital 2011-2018.
    PLoS One. 2020;15:e0232091.
    PubMed     Abstract available


  46. SINGH S, McDonald JT, Ilie G, Adisesh A, et al
    An examination of the association between lifetime history of prostate and pancreatic cancer diagnosis and occupation in a population sample of Canadians.
    PLoS One. 2020;15:e0227622.
    PubMed     Abstract available



  47. Retraction: Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties.
    PLoS One. 2020;15:e0233203.
    PubMed    


  48. MURAKAMI Y, Magome T, Matsumoto K, Sato T, et al
    Fully automated dose prediction using generative adversarial networks in prostate cancer patients.
    PLoS One. 2020;15:e0232697.
    PubMed     Abstract available


  49. NGO D, Baumgartner R, Mt-Isa S, Feng D, et al
    Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.
    PLoS One. 2020;15:e0229336.
    PubMed     Abstract available


  50. BRASIL DA COSTA FH, Lewis MS, Truong A, Carson DD, et al
    SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models.
    PLoS One. 2020;15:e0230354.
    PubMed     Abstract available


  51. CHAURASIYA S, Widmann S, Botero C, Lin CY, et al
    Estrogen receptor beta exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity.
    PLoS One. 2020;15:e0226057.
    PubMed     Abstract available


  52. MACAGNO A, Athanasiou A, Wittig A, Huber R, et al
    Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.
    PLoS One. 2020;15:e0233442.
    PubMed     Abstract available


  53. GRAHAM LS, Montgomery B, Cheng HH, Yu EY, et al
    Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
    PLoS One. 2020;15:e0233260.
    PubMed     Abstract available


  54. RIKKERT LG, de Rond L, van Dam A, van Leeuwen TG, et al
    Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging.
    PLoS One. 2020;15:e0233443.
    PubMed     Abstract available


  55. SENNOUNE SR, Nelius T, Jarvis C, Pruitt K, et al
    The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    PLoS One. 2020;15:e0234078.
    PubMed     Abstract available


  56. CHEN MM, Jahn JL, Barber JR, Han M, et al
    Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era.
    PLoS One. 2020;15:e0234391.
    PubMed     Abstract available


  57. HUSAINI Y, Tsai VW, Manandhar R, Zhang HP, et al
    Growth differentiation factor-15 slows the growth of murine prostate cancer by stimulating tumor immunity.
    PLoS One. 2020;15:e0233846.
    PubMed     Abstract available


  58. SHIN D, Shim SR, Kim CH
    Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
    PLoS One. 2020;15:e0234264.
    PubMed     Abstract available


  59. PACKEISER EM, Hewicker-Trautwein M, Thiemeyer H, Mohr A, et al
    Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
    PLoS One. 2020;15:e0230272.
    PubMed     Abstract available


  60. SILTARI A, Murtola TJ, Talala K, Taari K, et al
    Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.
    PLoS One. 2020;15:e0234269.
    PubMed     Abstract available


  61. WU YT, Chiang PH
    Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: Medium-term results from a single centre.
    PLoS One. 2020;15:e0236026.
    PubMed     Abstract available


  62. RHO MJ, Park J, Moon HW, Lee C, et al
    Dr. Answer AI for prostate cancer: Clinical outcome prediction model and service.
    PLoS One. 2020;15:e0236553.
    PubMed     Abstract available


  63. ARIK A, Dodd E, Streftaris G
    Cancer morbidity trends and regional differences in England-A Bayesian analysis.
    PLoS One. 2020;15:e0232844.
    PubMed     Abstract available


  64. DAOUK R, Bahmad HF, Saleh E, Monzer A, et al
    Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets.
    PLoS One. 2020;15:e0237442.
    PubMed     Abstract available


  65. LYNCH SM, Handorf E, Sorice KA, Blackman E, et al
    The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer.
    PLoS One. 2020;15:e0237332.
    PubMed     Abstract available


  66. ERB HHH, Bodenbender J, Handle F, Diehl T, et al
    Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
    PLoS One. 2020;15:e0237248.
    PubMed     Abstract available


  67. BOU-DARGHAM MJ, Sang QA
    Secretome analysis reveals upregulated granzyme B in human androgen-repressed prostate cancer cells with mesenchymal and invasive phenotype.
    PLoS One. 2020;15:e0237222.
    PubMed     Abstract available


  68. PAPANDRIANOS N, Papageorgiou E, Anagnostis A, Papageorgiou K, et al
    Bone metastasis classification using whole body images from prostate cancer patients based on convolutional neural networks application.
    PLoS One. 2020;15:e0237213.
    PubMed     Abstract available


  69. YAMADA Y, Teshima T, Fujimura T, Sato Y, et al
    Comparison of perioperative outcomes in elderly (age >== 75 years) vs. younger men undergoing robot-assisted radical prostatectomy.
    PLoS One. 2020;15:e0234113.
    PubMed     Abstract available


  70. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
    Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
    PLoS One. 2020;15:e0233397.
    PubMed     Abstract available


  71. STROOMBERG HV, Jorgensen A, Brasso K, Nielsen JE, et al
    Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients.
    PLoS One. 2020;15:e0238814.
    PubMed     Abstract available


  72. GROARKE A, Curtis R, Skelton J, Groarke JM, et al
    Quality of life and adjustment in men with prostate cancer: Interplay of stress, threat and resilience.
    PLoS One. 2020;15:e0239469.
    PubMed     Abstract available


  73. ALADWANI M, Lophatananon A, Robinson F, Rahman A, et al
    Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study.
    PLoS One. 2020;15:e0238928.
    PubMed     Abstract available


  74. MISHRA MV, Thayer WM, Janssen E, Hoppe B, et al
    Patient preferences for reducing bowel adverse events following prostate radiotherapy.
    PLoS One. 2020;15:e0235616.
    PubMed     Abstract available


  75. HONG S, Youk T, Lee SJ, Kim KM, et al
    Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
    PLoS One. 2020;15:e0234927.
    PubMed     Abstract available


  76. CARLSON AS, Acevedo RI, Lim DM, Gulati R, et al
    Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    PLoS One. 2020;15:e0239686.
    PubMed     Abstract available


  77. GONCU B, Sevgi E, Kizilarslan Hancer C, Gokay G, et al
    Differential anti-proliferative and apoptotic effects of lichen species on human prostate carcinoma cells.
    PLoS One. 2020;15:e0238303.
    PubMed     Abstract available


  78. YONG C, Moose DL, Bannick N, Gutierrez WR, et al
    Locally invasive, castrate-resistant prostate cancer in a Pten/Trp53 double knockout mouse model of prostate cancer monitored with non-invasive bioluminescent imaging.
    PLoS One. 2020;15:e0232807.
    PubMed     Abstract available


  79. FIORICA PN, Schubert R, Morris JD, Abdul Sami M, et al
    Multi-ethnic transcriptome-wide association study of prostate cancer.
    PLoS One. 2020;15:e0236209.
    PubMed     Abstract available


  80. LI AH, Palmer KS, Taljaard M, Paterson JM, et al
    Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study.
    PLoS One. 2020;15:e0236480.
    PubMed     Abstract available


  81. SANDEMAN K, Eineluoto JT, Pohjonen J, Erickson A, et al
    Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
    PLoS One. 2020;15:e0235779.
    PubMed     Abstract available


  82. MEIJER D, Jansen BHE, Wondergem M, Bodar YJL, et al
    Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
    PLoS One. 2020;15:e0239414.
    PubMed     Abstract available


  83. SARIISIK E, Zistl D, Docheva D, Schilling AF, et al
    Inadequate tissue mineralization promotes cancer cell attachment.
    PLoS One. 2020;15:e0237116.
    PubMed     Abstract available


  84. SONG Y, Zhang J, Zhang YD, Hou Y, et al
    FeAture Explorer (FAE): A tool for developing and comparing radiomics models.
    PLoS One. 2020;15:e0237587.
    PubMed     Abstract available



  85. Correction: MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer.
    PLoS One. 2020;15:e0241462.
    PubMed     Abstract available


  86. KALINAUSKAITE G, Senger C, Kluge A, Furth C, et al
    68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
    PLoS One. 2020;15:e0240892.
    PubMed     Abstract available


  87. KATONGOLE P, Sande OJ, Yusuf M, Joloba M, et al
    Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2015 and 2019 at the Uganda Cancer Institute.
    PLoS One. 2020;15:e0236458.
    PubMed     Abstract available


  88. ZWAANS BMM, Nicolai HE, Chancellor MB, Lamb LE, et al
    Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine.
    PLoS One. 2020;15:e0241388.
    PubMed     Abstract available


  89. BAIO G, Fabbi M, Cilli M, Rosa F, et al
    Manganese-enhanced MRI (MEMRI) in breast and prostate cancers: Preliminary results exploring the potential role of calcium receptors.
    PLoS One. 2020;15:e0224414.
    PubMed     Abstract available


  90. SINGH JP, Dagar M, Dagar G, Kumar S, et al
    Activation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells.
    PLoS One. 2020;15:e0226056.
    PubMed     Abstract available


  91. HAN C, Yu G, Mao Y, Song S, et al
    LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
    PLoS One. 2020;15:e0240801.
    PubMed     Abstract available


  92. NICHOLAS TR, Meng J, Greulich BM, Morris TS, et al
    --A high-throughput screen identifies inhibitors of the interaction between the oncogenic transcription factor ERG and the cofactor EWS.
    PLoS One. 2020;15:e0238999.
    PubMed     Abstract available


  93. TAKAKUSAGI Y, Oike T, Kano K, Anno W, et al
    Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer.
    PLoS One. 2020;15:e0241636.
    PubMed     Abstract available


  94. MCNABB E, Al-Mahrouki A, Law N, McKay S, et al
    Ultrasound-stimulated microbubble radiation enhancement of tumors: Single-dose and fractionated treatment evaluation.
    PLoS One. 2020;15:e0239456.
    PubMed     Abstract available


  95. HOTKER AM, Bluthgen C, Rupp NJ, Schneider AF, et al
    Comparison of the PI-RADS 2.1 scoring system to PI-RADS 2.0: Impact on diagnostic accuracy and inter-reader agreement.
    PLoS One. 2020;15:e0239975.
    PubMed     Abstract available


  96. CUNNINGHAM J, Thuijsman F, Peeters R, Viossat Y, et al
    Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.
    PLoS One. 2020;15:e0243386.
    PubMed     Abstract available


  97. FRENDL DM, FitzGerald G, Epstein MM, Allison JJ, et al
    Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool.
    PLoS One. 2020;15:e0240039.
    PubMed     Abstract available


  98. BRADY L, Hayes B, Sheill G, Baird AM, et al
    Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial.
    PLoS One. 2020;15:e0243928.
    PubMed     Abstract available


  99. ISHIYAMA Y, Shimbo M, Iizuka J, Deshpande G, et al
    Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
    PLoS One. 2020;15:e0244149.
    PubMed     Abstract available


  100. GEDEBORG R, Garmo H, Robinson D, Stattin P, et al
    Prescription-based prediction of baseline mortality risk among older men.
    PLoS One. 2020;15:e0241439.
    PubMed     Abstract available


  101. SHIM M, Bang WJ, Oh CY, Lee YS, et al
    Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.
    PLoS One. 2020;15:e0244660.
    PubMed     Abstract available


  102. GEVAERT T, Van Eycke YR, Vanden Broeck T, Van Poppel H, et al
    The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
    PLoS One. 2020;15:e0244663.
    PubMed     Abstract available


  103. GONCU B, Sevgi E, Hancer CK, Gokay G, et al
    Correction: Differential anti-proliferative and apoptotic effects of lichen species on human prostate carcinoma cells.
    PLoS One. 2020;15:e0244831.
    PubMed     Abstract available


  104. KIM HY, Lee DS
    A role for phosphodiesterase type 5 inhibitors in remodelling the urinary bladder after radiation exposure.
    PLoS One. 2020;15:e0242006.
    PubMed     Abstract available


  105. DAHL HC, Kanchwala M, Thomas-Jardin SE, Sandhu A, et al
    Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
    PLoS One. 2020;15:e0242970.
    PubMed     Abstract available


  106. FALLARA G, Lissbrant IF, Styrke J, Montorsi F, et al
    Observational study on time on treatment with abiraterone and enzalutamide.
    PLoS One. 2020;15:e0244462.
    PubMed     Abstract available


    January 2019
  107. PAL G, Ogunwobi OO
    Copy number-based quantification assay for non-invasive detection of PVT1-derived transcripts.
    PLoS One. 2019;14:e0226620.
    PubMed     Abstract available


  108. SU SY, Lee WC
    Age-period-cohort analysis with a constant-relative-variation constraint for an apportionment of period and cohort slopes.
    PLoS One. 2019;14:e0226678.
    PubMed     Abstract available


  109. PATEL DI, Abuchowski K, Bedolla R, Rivas P, et al
    Nexrutine and exercise similarly prevent high grade prostate tumors in transgenic mouse model.
    PLoS One. 2019;14:e0226187.
    PubMed     Abstract available


  110. SHARMA D, Giles A, Hashim A, Yip J, et al
    Ultrasound microbubble potentiated enhancement of hyperthermia-effect in tumours.
    PLoS One. 2019;14:e0226475.
    PubMed     Abstract available


  111. BOOTH N, Rissanen P, Tammela TLJ, Kujala P, et al
    Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    PLoS One. 2019;14:e0224479.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: